In the case of pre-treatment auto-aggression, the PD-1 blockade usually leads to its exacerbation, but symptoms are reduced after symptomatic or substitution treatment and usually do not affect the possibility of continuing immunotherapy (this does not apply to serious autoimmune diseases such as lupus or systemic sclerosis) [14,21]. This evidence concerns the gene PDCD1 and autoimmune disease.